

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

Date: 9th January, 2026

Dear Sir/Madam,

This has reference to your query received to us on 7th January, 2026 regarding the **Outcome of Board Meeting – Financial Results** submitted by **Ambey Laboratories Limited** to the Exchange for the half year ended September 30, 2025.

In this regard, we hereby submit our point-wise clarification as under:

a. Comparative Figures for Consolidated Financial Results

The consolidated financial results for the period under review have been prepared for the first time, consequent to the Company acquiring control over its subsidiary during the current financial year. In the corresponding previous period, the Company did not have any subsidiary requiring consolidation and, accordingly, consolidated financial statements were not applicable.

In this regard, reference is invited to **Accounting Standard (AS) 21 – Consolidated Financial Statements, Paragraph 30 (Transitional Provisions)**, which specifically provides that “*on the first occasion that consolidated financial statements are presented, comparative figures for the previous period need not be presented*”. Further, the Ministry of Corporate Affairs has clarified, vide footnote inserted under the Companies (Accounting Standards) Rules, 2021, that the transitional provisions contained in Paragraph 30 are applicable to standards notified under the Companies (Accounting Standards) Rules, 2006 as well as Companies (Accounting Standards) Rules, 2021.

Accordingly, non-presentation of comparative consolidated figures for the corresponding previous period is in accordance with the aforesaid accounting standard and represents a case of first-time applicability of consolidation.

b. Disclosure of Utilisation of Issue Proceeds

We further confirm that the disclosure relating to utilisation of issue proceeds forms part of the financial information reviewed by us during the limited review of the financial results. The Limited Review Report issued under Regulation 33 of SEBI (LODR) Regulations, 2015, which has been duly signed by us, covers the said disclosure (**annexed with this letter**).

In our view, since the utilisation of issue proceeds has already been examined and reported upon as part of the signed Limited Review Report, a separate auditor certification is not required in this regard.

We hope that the above clarifications satisfactorily address your query.

Kindly take the above clarification on record.

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

Yours Faithfully

For: AMBEY LABORATORIES LIMITED

Himanshu Kukreja

Designation: Company Secretary

Membership No: A64853



F.R.N. 022743N

KAPISH JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the half year ended 30 September 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Ambey Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Ambey Laboratories Limited** ("the Company") for the half year ended 30 September 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.




5. During the half year ended on 30 September 2025, the Company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilized for the purposes detailed in the table below.

Object of issue	Amount received (25% of total value)	Amount utilized till September 30, 2025	Amount unutilized till September 30, 2025	Rs. In Lakhs
				Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	1,250.00	1,250.00	-	N/A

For **KAPISH JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration No. 022743N



CA Kapish Jain
Partner
M. No.: 514162
UDIN: 25514162BMJVGE8958
Place: New Delhi
Date: 14 November 2025